Lotte Biologics said Wednesday it has signed a contract manufacturing and development (CDMO) agreement with a U.S.-based biotech company specializing in cancer to produce antibody drug substance and develop related processes.
Under the deal, Lotte Biologics will produce antibody samples needed for global late-stage clinical trials and optimize large-scale processes, supported by its Syracuse Bio Campus in New York.
The company said the project is designed with follow-on clinical work and commercialization in mind, beyond producing clinical samples. It plans to support the candidate’s clinical and commercialization readiness using its large-scale facilities and manufacturing capabilities.
Lotte Biologics said it is using the Syracuse campus as a base to expand collaboration with customers and will link it with its Songdo Bio Campus, scheduled for completion this year, to strengthen customized CDMO services built on integrated quality operations and to enhance supply chain management capabilities.
A Lotte Biologics official said the order “has laid the groundwork for large-scale contracts” with cancer-focused biotech companies and added the company will work to ensure it leads to commercialization and additional orders.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.